Tudor Investment Corp’s Verve Therapeutics VERV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-36,975
Closed -$169K 3791
2025
Q1
$169K Buy
+36,975
New +$248K ﹤0.01% 2894
2024
Q4
Sell
-41,544
Closed -$201K 3539
2024
Q3
$201K Sell
41,544
-1,105
-3% -$6.42K ﹤0.01% 2537
2024
Q2
$208K Buy
42,649
+925
+2% +$5.81K ﹤0.01% 2151
2024
Q1
$554K Buy
+41,724
New +$553K ﹤0.01% 1610
2023
Q4
Sell
-31,744
Closed -$421K 2939
2023
Q3
$421K Buy
31,744
+901
+3% +$14.5K ﹤0.01% 1761
2023
Q2
$578K Sell
30,843
-8,931
-22% -$149K 0.01% 1630
2023
Q1
$574K Buy
39,774
+13,489
+51% +$264K 0.01% 1537
2022
Q4
$509K Buy
+26,285
New +$696K 0.01% 1570
2022
Q2
Sell
-24,216
Closed -$553K 2538
2022
Q1
$553K Buy
+24,216
New +$692K 0.01% 1217
2021
Q3
Sell
-7,904
Closed -$476K 2823
2021
Q2
$476K Buy
+7,904
New +$328K 0.01% 1192

Other funds holding VERV

Tudor Investment Corp's VERV Position: Q2 2025 in Review

Tudor Investment Corp sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 36,975 shares — an estimated $169K sold.

Tudor Investment Corp first reported a position in VERV in Q2 2021 and held it in 10 quarters. The position peaked at $578K in Q2 2023. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Tudor Investment Corp reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Tudor Investment Corp sold 36,975 Verve Therapeutics shares in Q2 2025, an estimated $169K.
  • Tudor Investment Corp first reported a position in Verve Therapeutics in Q2 2021 and held it in 10 quarters.
  • Tudor Investment Corp's Verve Therapeutics position peaked at $578K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Tudor Investment Corp's 13F filing for Q2 2025, filed 14 Aug 2025.